A detailed history of Israel Englander (Millennium Management LLC) transactions in Altimmune, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 40,000 shares of ALT stock, worth $347,200. This represents 0.0% of its overall portfolio holdings.

Number of Shares
40,000
Previous 13,355 199.51%
Holding current value
$347,200
Previous $88,000 178.41%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$5.5 - $8.1 $499,389 - $735,463
90,798 Added 679.88%
104,153 $639,000
Q2 2024

Aug 14, 2024

SELL
$5.91 - $10.23 $9.32 Million - $16.1 Million
-1,576,795 Reduced 99.16%
13,355 $88,000
Q1 2024

May 15, 2024

BUY
$8.22 - $13.81 $11.6 Million - $19.6 Million
1,416,009 Added 813.14%
1,590,150 $16.2 Million
Q4 2023

Feb 14, 2024

SELL
$2.14 - $11.62 $1.64 Million - $8.92 Million
-767,953 Reduced 81.52%
174,141 $1.96 Million
Q2 2023

Aug 14, 2023

SELL
$3.45 - $5.97 $436,945 - $756,106
-126,651 Reduced 11.85%
942,094 $3.33 Million
Q1 2023

May 15, 2023

BUY
$4.19 - $16.83 $3.87 Million - $15.6 Million
924,007 Added 638.4%
1,068,745 $4.51 Million
Q4 2022

Feb 14, 2023

SELL
$8.74 - $16.45 $3.16 Million - $5.94 Million
-360,989 Reduced 71.38%
144,738 $2.38 Million
Q3 2022

Nov 14, 2022

SELL
$10.67 - $22.41 $3.4 Million - $7.15 Million
-318,921 Reduced 38.67%
505,727 $6.46 Million
Q2 2022

Aug 15, 2022

BUY
$3.94 - $11.77 $502,302 - $1.5 Million
127,488 Added 18.29%
824,648 $9.65 Million
Q1 2022

May 16, 2022

BUY
$5.9 - $9.45 $3.47 Million - $5.56 Million
588,302 Added 540.43%
697,160 $4.25 Million
Q4 2021

Feb 14, 2022

SELL
$8.69 - $12.48 $255,451 - $366,862
-29,396 Reduced 21.26%
108,858 $997,000
Q3 2021

Nov 15, 2021

SELL
$8.43 - $16.81 $5.01 Million - $9.99 Million
-594,488 Reduced 81.13%
138,254 $1.56 Million
Q1 2021

May 17, 2021

BUY
$12.71 - $24.31 $4.52 Million - $8.64 Million
355,554 Added 94.26%
732,742 $10.4 Million
Q4 2020

Feb 16, 2021

BUY
$7.84 - $14.22 $775,728 - $1.41 Million
98,945 Added 35.56%
377,188 $4.26 Million
Q3 2020

Nov 16, 2020

SELL
$9.93 - $33.26 $2.27 Million - $7.59 Million
-228,281 Reduced 45.07%
278,243 $3.67 Million
Q2 2020

Aug 14, 2020

BUY
$2.9 - $10.71 $1.47 Million - $5.42 Million
506,524 New
506,524 $5.43 Million

Others Institutions Holding ALT

About Altimmune, Inc.


  • Ticker ALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,025,300
  • Market Cap $426M
  • Description
  • Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...
More about ALT
Track Israel Englander's Portfolio

Track Israel Englander Portfolio

Follow Israel Englander (Millennium Management LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.